ONE-TWENTY TWO: Trading Financial Markets
Since the year 2000, delivering a different narrative for students and fans of financial markets: stocks, options, currencies, Bitcoin, and more…
AT40 = 25.5% of stocks are trading above their respective 40-day moving averages (DMAs)AT200 = 23.4% of stocks are trading above their respective 200DMAs (just off a 32-month low)VIX = 23.2 (as high as 24.7)Short-term Trading Call: cautiously bullish CommentaryI am surprised the stock market has yet to close in oversold conditions. AT40 (T2108), the … Read more
Five months ago, I made the case for bottom-fishing in DexCom (DXCM) following the news of competitor’s Abbott (ABT) product approval. The trade was looking shaky a few weeks later when the stock made a minor new closing low from that price collapse. November earnings produced the catalyst to confirm the bottom, and the stock … Read more
AT40 = 67.5% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 63.2% of stocks are trading above their respective 200DMAs VIX = 9.2 Short-term Trading Call: cautiously bullish Commentary In my last Above the 40 I complained that market breadth was once again suffering thanks to an S&P 500 (SPY) … Read more
AT40 = 48.1% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 54.9% of stocks are trading above their respective 200DMAs VIX = 11.3 Short-term Trading Call: cautiously bullish Commentary It was by the slimmest of margins, but the S&P 500 (SPY) finally ended a week with a loss. After 8 … Read more
DexCom (DXCM) is a maker of continuous glucose monitoring (CGM) systems. Last week, the stock of the company cratered after Abbott Laboratories (ABT) received FDA approval of its competing FreeStyle Libre flash CGM. It is the first system that allows diabetics to check and monitor glucose levels without sticking themselves. In response to the news, … Read more